Optinose Announces Departure of Acting Chief Financial Officer
Optinose (NASDAQ:OPTN) announced that Michele Janis, Acting Chief Financial Officer, will depart for a CFO role at another company, effective December 30, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Optinose (NASDAQ:OPTN) announced that Michele Janis, Acting Chief Financial Officer, will depart for a CFO role at another company, effective December 30, 2022. CEO Peter Miller praised Janis for her over 11 years of service, highlighting her role in the company's development. Anthony Krick, Vice President, will remain as Chief Accounting Officer, overseeing financial reporting and daily financial operations. Jonathan Neely will continue leading investor relations. The company remains focused on the needs of ENT and allergy patients.
Positive
- Michele Janis significantly contributed to Optinose's growth over 11 years.
- Leadership team remains stable with Anthony Krick and Jonathan Neely continuing in key roles.
Negative
- Departure of CFO may lead to temporary instability in financial management.
Details
News Market Reaction – OPTN
The recorded move for OPTN in the trading session of this news was -7.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022.
Chief Executive Officer Peter Miller stated “On behalf of our entire team, I would like to express our deep appreciation to Michele for her commitment and contributions to Optinose where she has been a valuable and trusted partner for over 11 years. Michele was instrumental in building the finance and accounting functions from the ground up and leading the Company’s transition from a privately held development stage to a publicly held commercial stage company. We wish Michele continued success in her new role.”
Anthony Krick, Vice President, Controller, will continue to serve as Vice President and Chief Accounting Officer and be responsible for financial reporting and managing the day to-day activities of the finance & accounting team. Jonathan Neely, Vice President, Investor Relations & Business Development will continue to lead investor communications. Mr. Krick and Mr. Neely will both continue to serve on the Company’s leadership team.
“It’s been a privilege to have played a key role in the evolution of Optinose and to have been part of an exceptionally talented team over the past 11+ years,” said Michele Janis, departing Acting Chief Financial Officer.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.